A Phase IB Study of Pembrolizumab in Combination with Pemetrexed and Oxaliplatin in Patients with Chemo-refractory Metastatic Colorectal Cancer
Protocol Chair: James J. Lee, MD, PhD
Protocol Officer: Thomas George, MD
Primary Objective: 1) to establish the recommended Phase II dose (RP2D) of pembrolizumab in combination with pemetrexed and oxaliplatin and 2) evaluate the antitumor efficacy.
Patient Population: Metastatic Colorectal Cancer
Target Accrual: 33 patients
Status: Recruiting patients
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402